Our Scientific Advisory Board invites thought leaders from across the communities of biomedical research, engineering, and data science to participate in planning our programs. These are focused upon stimulating cross-silo understanding and collaboration. Through ongoing activities such as roundtales, webinars, and symposia, our SAB members are able to explore new perspectives and share their own.

Scientific Advisory Board Members
(scroll for bios)

Dr. Anka G. Ehrhardt, Director, Clinical Flow Cytometry - Bristol-Myers Squibb
David C. Fritzinger, Fritzinger Biopharma Consulting, LLC
Bob Gold, Founder and CEO - GoMo Health
Terence A. Kelly, President and CEO - CoMentis, Inc
Sathapana (Sam) Kongsamut, Owner and Principal - Rudder Serendip LLC
Gail S. Krebs, Founder - FGR Diagnostics
Winston Kuo, Chief Technology Officer & Head of Business Development - CloudHealth Genomics
Ben Locwin,  President - Healthcare Science Advisors
Bozena "Bo" B. Michniak-Kohn, Professor of Pharmaceutics - Ernest Mario School of Pharmacy
Director - Center for Dermal Research (CDR) & Laboratory for Drug Delivery (LDD), Rutgers
John Pace, Executive Director, Scientific Research - ATCC Center for Translational Microbiology
Institute for Life Science Entrepreneurship Kean University
Wade Trappe, IEEE Fellow, Professor, Department of Electrical and Computer Engineering, Associate Director, WINLAB,
Rutgers University
Hanqing Xie, President / Owner - Synatom Research LLC
Howard Young, Senior Investigator Cancer & Inflammation Program - Center for Cancer Research NCI at Frederick, MD

Dr. Anka G. Ehrhardt, Ph.D.
Director, Clinical Flow Cytometry - Bristol-Myers Squibb
LinkedIn Page

Dr. Ehrhardt is a biophysicist, holding a Ph.D. in physiology.  As a leader in technology-based biological research, she is known for driving collaboration and pragmatic innovation.  Throughout her career, both in academia and the pharmaceutical industry, Dr. Ehrhardt has developed and implemented innovative assays to drive programs and achieve results. 

As head of a technology core facility in a Fortune 500 pharmaceutical company, Dr. Ehrhardt developed and managed a large number of successful collaborations.  As member of the BRC Scientific Advisory Board, she brings her experience as collaborator and leader, and as subject matter expert in imaging and flow cytometry together with her enthusiasm for driving connectivity in biopaharmaceutical research.

David C. Fritzinger, Ph.D.
Fritzinger Biopharma Consulting, LLC
LinkedIn Page

Dr. Fritzinger is a seasoned molecular biologist and protein chemist with over 10 years experience working on the early-stage development of protein therapeutics. He currently provides consulting services in molecular biology, protein chemistry, and biologics development. 

As Associate Professor at the University of Hawaii Cancer Center, he performed structure/function studies on human complement C3. 

While at the UH Cancer Center, Dr. Fritzinger co-founded the biotech startup, InCode Biopharmaceutics, Inc., based on the Intellectual Property from his laboratory. As Chief Scientific Officer at InCode, he directed all discovery research for the company and managed the work of both CROs and CMOs in producing large quantities of the company’s lead protein, both in insect and mammalian cells. Previous to his work at UH and InCode, Dr. Fritzinger was the director of the DNA sequencing and genotyping core at Myriad Genetics, Inc. 

He received his BS in Chemistry from Purdue University and his Ph.D. from the University of Massachusetts at Amherst, where he studied conformational changes in tRNA caused by changes in solution conditions or aminoacylation. Dr. Fritzinger performed his post-doctoral research at the University of Bristol, working in the lab of Nigel Brown. 

Bob Gold
Founder and CEO - GoMo Health
LinkedIn Page

Bob Gold is one of the world's leading behavioral technologists with more than 20 years applied research and development in the growing field of digital to human persuasion and motivation.

Bob applies his methodologies and techniques to help create a more sustainable healthcare infrastructure for hospitals, health systems and providers, pharmaceutical companies, and insurers as more patients need to be treated and engaged within their day-to-day lifestyle. He is especially focused on remote care coordination (pre/post discharge) and telehealth, with growing success in the management both of chronic conditions and episodic pre and post-discharge management, and identifying and taking advantage of opportunities for transitional care reimbursement opportunities associated with the exchange of this information. 

Bob focuses his energy on recrafting clinical care plans into behaviorally-based remote care coordination and telehealth patient engagement protocols to produce better outcomes, and evidence based data sets and increase compliance; with the emphasis on the delivery of dynamic content to support approved protocols with a more personalized, disciplined, and nurturing experience within the framework of a person's lifestyle and typical day.

Terence A. Kelly, PhD. 
President and CEO - CoMentis, Inc
LinkedIn Page

Dr. Kelly has over 25 years of experience as a scientist and executive in the pharmaceutical industry starting as a medicinal chemist in 1990.  After a successful early career developing LFA-1 antagonists, he was asked to lead Boehringer Ingelheim’s US-based medicinal chemistry department, which included 145 scientists in the high throughput screening, computational chemistry, structural biology, combinatorial chemistry and medicinal chemistry groups.  He joined CoMentis in 2010 as Chief Scientific Officer responsible for the Oklahoma City Research Center and the overall research portfolio.  He was promoted to Chief Executive Officer in 2011.

Dr. Kelly completed his BS degree in chemistry at Rensselaer Polytechnic Institute and his Ph.D. degree in chemistry at the University of Texas at Austin. He completed postdoctoral work in natural products synthesis at Yale University and holds an MBA from New York University, Stern School of Business.  Dr. Kelly is the co-author on over 25 scientific publications and an inventor on multiple patents.

Sathapana (Sam) Kongsamut, Ph.D.
Owner and Principal - Rudder Serendip LLC
LinkedIn Page

Sam Kongsamut obtained his PhD at the University of Chicago and had postdoctoral training at Cornell and Yale Universities. He joined the pharmaceutical industry in 1991, working for a succession of five different companies (Hoechst-Roussel Pharmaceuticals Inc, Hoechst Marion Roussel, Aventis, sanofi aventis. now sanofi), and experiencing two mergers, one takeover, and one "transformation" without moving anywhere. Sam has managed various-sized groups of scientists in biochemical pharmacology that served multiple project teams in the neuroscience area, and has been a member of the CNS Board that managed the CNS project portfolio. He has led or worked on a variety of drug discovery and development projects covering a range of neuroscience areas (OCD, anxiety-depression, schizophrenia, Alzheimer's Disease, Parkinson's Disease, sleep disorders, multiple sclerosis, spinal cord injury, stroke), helping to translate animal pharmacology to human pharmacology, including being involved with two drugs that are now helping patients. More recently, Sam was Director of External Innovation at sanofi-aventis, using his experience to identify opportunities for collaboration and licensing for broad therapeutic interests within the Aging Unit. Since leaving Sanofi in 2012, Sam founded Rudder Serendip LLC (steering from the rear close to the data towards serendipity), a consulting practice that serves clients at universities, foundations and biotechnology companies with advice on R&D plans and business development.

Gail S. Krebs
Founder - FGR Diagnostics
LinkedIn Page

FGR DIAGNOSTICS founder, Gail S. Krebs, MHA, is a recognized expert in the organization, financing, and delivery of healthcare services. A former research professor at the University of New Hampshire, Department of Health Management and Policy, she consults to health insurers, employers, and government agencies on the financial impact of health benefits programs. She presents "Strategic Pregnancy: Aligning Maternity Management with Business Performance."  Widely published, she led the first national study of managed maternity care products -- disseminated to the industry as a white paper by The Travelers and at conferences sponsored by the Washington Business Group on Health. She holds the MHA degree from Cornell University, Sloan Program in Health Services Administration.


Winston Kuo
Chief Technology Officer & Head of Business Development - CloudHealth Genomics
LinkedIn Page

Dr. Winston Patrick Kuo is the Chief Technology Officer and Head of Business Development for CloudHealth Genomics based in Boston, MA and Shanghai, China. CloudHealth Genomics, Ltd. is a comprehensive genomics-based precision medicine solutions provider focused on bringing the best practices in diagnostics through innovation and high-throughput genomics to the global healthcare ecosystem. The concept is to generate population-based genomic data, to understand, diagnose and provide solutions to treat disease with an emphasis of using “big data” to develop preventive medicine metrics and guidance to develop precision medicines for a healthier society. Dr. Kuo has spent over 20 years in academia and 4 years in industry. Prior to industry, Dr. Kuo was Assistant Professor in the Department of Developmental Biology at Harvard School of Dental Medicine and Director and founder of the Harvard Clinical and Translational Science – Laboratory for Innovative Translational Technologies at Harvard Medical School

Ben Locwin, Ph.D., MBA
President - Healthcare Science Advisors
LinkedIn Page

Dr. Ben Locwin is an author of a wide variety of scientific articles in books and magazines and gives worldwide speaking engagements on healthcare topics. He is an expert contact for the American Association of Pharmaceutical Scientists (AAPS), a committee member of the American Statistical Association (ASA), and a leader in the Association for Talent Development's Healthcare Community of Practice.

Bozena "Bo" B. Michniak-Kohn, Ph.D., FAAPS, M.R.Pharm.S.
Professor of Pharmaceutics - Ernest Mario School of Pharmacy
Director - Center for Dermal Research (CDR) & Laboratory for Drug Delivery (LDD)
NJ Center for Biomaterials, Life Sciences Building - Rutgers
LinkedIn Page

Dr. Bozena B. Michniak-Kohn is a tenured Professor of Pharmaceutics at the Ernest Mario School of Pharmacy, and Founder /Director of the Center for Dermal Research CDR at Rutgers-The State University of New Jersey, Piscataway, NJ. She is also the Director of the Laboratory for Drug Delivery of the New Jersey Center for Biomaterials (NJCBM). Her main focus is topical, transdermal and buccal drug delivery. Dr. Michniak-Kohn has over 35 years experience in design & optimization of topically applied formulations and transdermal patches. She holds patents for novel drug carrier approaches for dermatologicals. She is a member of graduate programs at Rutgers in Pharmaceutical Sciences, Biomedical Engineering, Chemical and Biochemical Engineering, Chemistry and Chemical Biology as well as the RWJ Graduate School of Biomedical Sciences. Dr. Michniak-Kohn received her B. Sc. (Honors) in Pharmacy and Ph.D. in Pharmacology from the U.K. Dr. Michniak-Kohn has directed over 50 Ph.D. and Masters students and the work resulted in over 120 peer-reviewed manuscripts, over 420 abstracts, 2 books, and 35 book chapters. She is a member of 10 journal editorial boards, several scientific advisory boards, member of Board of Trustees at TRI, Princeton and is a reviewer for about 42 pharmaceutical and drug delivery journals. For this work she was awarded Fellow status of the American Association of Pharmaceutical Scientists (AAPS) in 2008.

John Pace, Ph.D.
Executive Director, Scientific Research - ATCC Center for Translational Microbiology Institute for Life Science Entrepreneurship Kean University
LinkedIn Page

As the senior most position within the organization, Dr. Pace is responsible for helping to set the direction of the Center, including the establishment of near-term and long-term strategic and operating plans in partnership with the Executive Committee and founders of the Center. 

He is an experienced biotech/pharmaceutical industry scientist with more than 25 years’ experience spanning pathogenesis research, and antibiotic and vaccine R&D.  He has led efforts that resulted in the evaluation of 14 clinical candidates, and the approved antibiotic drugs AvyCaz, Altabax/Altargo, and Vibativ the latter of which he is also co-inventor.  

He has worked for anti-infective companies on both coasts, as well as in France and Denmark, and is an Adjunct Associate Professor with the Biomanufacturing Research Institute and Technology Enterprise-North Carolina Central University. 

Wade.jpg

Wade Trappe
IEEE Fellow
Professor, Department of Electrical and Computer Engineering
Associate Director, WINLAB
Rutgers University

Wade Trappe received his Ph.D. in Applied Mathematics and Scientific Computing from the University of Maryland in 2002. He is an IEEE Fellow for his contributions to the field of communications and network security. He is a Professor in the Electrical and Computer Engineering Department at Rutgers University, and Associate Director of the Wireless Information Network Laboratory (WINLAB), where he directs WINLAB’s research in wireless security. He has led several federally funded projects in the area of cybersecurity and communication systems. Beyond his expertise in cybersecurity, he has conducted research across a wide array of fields, including acoustics, mathematical modeling, and game theory. Recently, he has been working on mathematical modeling of various biological systems.

Hanqing Xie, Ph. D.
President / Owner - Synatom Research LLC
LinkedIn Page

As the senior most position within the organization, Dr. Pace is responsible for helping to set the direction of the Center, including the establishment of near-term and long-term strategic and operating plans in partnership with the Executive Committee and founders of the Center. 

He is an experienced biotech/pharmaceutical industry scientist with more than 25 years’ experience spanning pathogenesis research, and antibiotic and vaccine R&D.  He has led efforts that resulted in the evaluation of 14 clinical candidates, and the approved antibiotic drugs AvyCaz, Altabax/Altargo, and Vibativ the latter of which he is also co-inventor.  

He has worked for anti-infective companies on both coasts, as well as in France and Denmark, and is an Adjunct Associate Professor with the Biomanufacturing Research Institute and Technology Enterprise-North Carolina Central University. 

Howard Young, Ph.D.
Senior Investigator Cancer & Inflammation Program - Center for Cancer Research NCI at Frederick, MD
LinkedIn Page

Howard Young received his PhD from the Department of Microbiology and Immunology at the University of Washington and did postdoctoral research under Drs. Edward Scolnick and Wade Parks at the National Cancer Institute.  He joined the National Cancer Institute in 1983 and became Deputy Chief of the NCI Laboratory of Experimental Immunology in 2006. His research has focused on the analysis of cytokine gene expression and signaling with a special emphasis on the molecular characterization of the transcriptional and posttranscriptional regulation of Interferon-g in NK cells.  Most recently, his laboratory has developed novel mouse models of lupus and aplastic anemia based on chronic expression of low levels of this important immunoregulatory molecule in the murine C57BL/6 genetic background and the Balb/c genetic background, respectively. He is also collaborating with a laboratory in Malaysia on the development of probiotic microorganisms as carriers for vaccine delivery systems.  

Dr. Young is a former President of the International Society for Interferon and Cytokine Research and is a co-recipient (with Dr. Sidney Pestka) of the first Distinguished Service Award from the ISICR, is a two time recipient of the National Cancer Institute Director’s Award for Mentoring and is a recipient of the National Public Service Award from the American Society for Public Administration and the National Academy of Public Administration.  He has also served as Chair of the Immunology Division of the American Society for Microbiology, Chair of the NIH Immunology Interest Group and Cytokine Interest Group and is a member of the American Academy of Microbiology.